News & Videos - SHIELD THERAPEUTICS ORD 1.5P

Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team 15-Nov-2023 / 07:30 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since...

Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering 25-Jul-2023 / 09:45 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has...

Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions 17-May-2023 / 07:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in...

Hardman & Co Research Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital 23-Jan-2023 / 11:15 GMT/BST Analyst interview | Life Sciences Q&A on Shield Therapeutics (STX) | Positioned for profitability with Viatris deal and its additional capitaltive Shield Therapeutics (STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews. Martin summarises a number of announcements made by the company recently,...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability 13-Jan-2023 / 07:15 GMT/BST Hardman & Co Research on Shield Therapeutics (STX): Positioned for growth and profitability Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awareness of the...

Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building 15-Sep-2022 / 13:52 GMT/BST Hardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building Shield Therapeutics (Shield) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US, in July 2021, the initial challenge was to greatly improve...

Hardman & Co Research Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous 12-Aug-2022 / 11:45 GMT/BST Hardman & Co Video | Analyst interview Shield Therapeutics (STX): Upside potential is enormous Shield Therapeutics (STX) is the topic of conversation when Martin Hall joins DirectorsTalk Interviews. Despite launching a drug into the US market, Shield has performed really badly over the past 12 months, Martin explains what happened, shares his thoughts on the considerable...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US 26-Jul-2022 / 07:15 GMT/BST Hardman & Co Research on Shield Therapeutics (STX): Looking to accelerate positive signals in the US Shield Therapeutics (Shield) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US in July 2021, the...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) - PBMs have bought in to Accrufer 02-March-2022 / 13:30 GMT/BST Hardman & Co Research on Shield Therapeutics (STX): PBMs have bought in to Accrufer Shield Therapeutics (Shield) is a commercial-stage pharma company delivering specialty products that address patients' unmet medical needs, with an initial focus on iron deficiency (ID). Following the US launch of Accrufer(R) in July 2021, the initial challenge was to greatly...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research 07-Oct-2021 / 09:45 GMT/BST Hardman & Co Life Sciences Investor Forum company research: Shield Therapeutics (STX) On 23 September we were delighted to host our second Life Sciences Investor Forum. At the live event, Greg Madison, Shield's CEO, answered questions ranging from the performance of Norgine B.V. to the US launch and, in particular, the sales growth of Accrufer(R). We would like...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) - Focused on US market penetration 20-Aug-2021 / 11:08 GMT/BST Hardman & Co Research: Focused on US market penetration Shield Therapeutics (Shield) is a commercial-stage pharmaceutical company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). Accrufer(R) has just been launched in the US by Shield, where the initial aim is to greatly improve market...

Hardman & Co Research Hardman & Co Video Event | Shield Therapeutics plc - Investor Forum 12-Aug-2021 / 07:25 GMT/BST Hardman & Co Video Event | Shield Therapeutics plc Investor Forum We are delighted to announce that Shield Therapeutics plc will be presenting at our next Investor Forum on Thursday 23 September at 5:00pm. The Investor Forum connects investors with companies looking for capital. Each company will present for 10-15 minutes, followed by an opportunity for Q&A. The Forum is being...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Accrufer launch on schedule 26-May-2021 / 10:35 GMT/BST Hardman & Co Research: Accrufer launch on schedule Shield Therapeutics (Shield) is a commercial-stage pharmaceutical company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru(R)/Accrufer(R) has been approved by the regulators in both Europe and the US. Following completion of a...

Edison Investment Research Limited Edison Investment Research Limited: Shield Therapeutics (STX): Beefing up for the US opportunity 02-Feb-2021 / 08:00 GMT/BST London, UK, 2 February 2021 Shield Therapeutics (STX): Beefing up for the US opportunity Shield Therapeutics' (STX's) shares fell sharply in December 2020 on the announcement that a US partnering deal would not be completed in 2020 and that the company is considering launching Accrufer itself in the US. We believe the market reaction has...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Reassessing the US opportunity 06-Jan-2021 / 07:15 GMT/BST Hardman & Co Research: Reassessing the US opportunity STX is a commercial-stage company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru (R) /Accrufer (R) has been approved by the regulators in both Europe and the US. For various reasons, STX has been unable to secure a...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Optimism over US deal 18-Sep-2020 / 13:30 GMT/BST Hardman & Co Research: Optimism over US deal STX is a commercial-stage company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru/Accrufer has been approved by the regulators in both Europe and the US. The company has an established commercial relationship with Norgine for Europe and...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Reassuring trading update 11-May-2020 / 13:15 GMT/BST Hardman & Co Res earch : Reassuring trading update Shield Therapeutics (STX) is a commercial-stage company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Feraccru/Accrufer has achieved regulatory approvals for both Europe and the US. The company has faced some unexpected...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Good demand for Feraccru in Europe 28-Jan-2020 / 12:15 GMT/BST Hardman & Co Res earch : Good demand for Feraccru in Europe Shield Therapeutics (STX) is a commercial-stage company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Recent news that the FDA had approved this drug for a broad indication opened up a market in the US...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Taking on China 14-Jan-2020 / 07:15 GMT/BST Hardman & Co Res earch : Taking on China Shield Therapeutics (STX) is a commercial-stage company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Recent news that the FDA had approved this drug for a broad indication opened up a market in the US currently worth over $1bn p.a. On 8...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): More choice for clinicians and patients 30-Oct-2019 / 07:30 GMT/BST Hardman & Co Res earch : More choice for clinicians and patients Shield Therapeutics (STX) is a commercial-stage company delivering specialty products that address unmet medical needs, with an initial focus on treating iron deficiency (ID) with Feraccru (R)/ Accrufer (R). FDA approval of Accrufer with a broad label in the US opens up a market currently worth...